drugset
drugset / Trial / NCT02387853

Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis

NCT02387853 ↗

Phase 2 Completed 117 enrolled LEO Pharma
NaSingle-groupOpen-labelTreatment

Summary

An international, multi-centre, prospective, open-label, non-controlled, single-group, 4-week trial in adolescent subjects with plaque psoriasis.

Timeline

Start
2016-03
Primary completion
2018-03-28
Completion
2018-03-28

Drugs

EvaluationDrugModalityDoseRoute
Subject LEO 90100 Unknown — Topical

Indications

psoriasis